9,060 Shares in Biohaven Ltd. (NYSE:BHVN) Purchased by Public Employees Retirement System of Ohio

Public Employees Retirement System of Ohio bought a new position in Biohaven Ltd. (NYSE:BHVN) during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 9,060 shares of the company’s stock, valued at approximately $236,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. US Bancorp DE boosted its stake in Biohaven by 19.1% in the first quarter. US Bancorp DE now owns 586 shares of the company’s stock valued at $70,000 after acquiring an additional 94 shares in the last quarter. Cetera Advisor Networks LLC acquired a new stake in Biohaven in the first quarter valued at approximately $332,000. AlphaCrest Capital Management LLC acquired a new stake in Biohaven in the first quarter valued at approximately $344,000. BlackRock Inc. boosted its stake in Biohaven by 0.5% in the first quarter. BlackRock Inc. now owns 4,656,866 shares of the company’s stock valued at $552,163,000 after acquiring an additional 21,586 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its stake in Biohaven by 55.3% in the first quarter. Dimensional Fund Advisors LP now owns 82,599 shares of the company’s stock valued at $9,794,000 after acquiring an additional 29,413 shares in the last quarter. 88.78% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Biohaven news, Director Irina Antonijevic sold 11,000 shares of the company’s stock in a transaction dated Friday, December 29th. The shares were sold at an average price of $41.79, for a total value of $459,690.00. Following the completion of the transaction, the director now owns 2,535 shares in the company, valued at $105,937.65. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 16.00% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have weighed in on BHVN shares. JPMorgan Chase & Co. raised their target price on shares of Biohaven from $32.00 to $56.00 and gave the company an “overweight” rating in a research note on Friday, February 23rd. UBS Group started coverage on shares of Biohaven in a report on Tuesday, February 6th. They issued a “buy” rating and a $59.00 price target for the company. Robert W. Baird started coverage on shares of Biohaven in a report on Friday, December 8th. They issued an “outperform” rating and a $58.00 price target for the company. HC Wainwright raised their price target on shares of Biohaven from $50.00 to $63.00 and gave the stock a “buy” rating in a report on Monday, March 4th. Finally, TD Cowen raised their price target on shares of Biohaven from $35.00 to $55.00 and gave the stock an “outperform” rating in a report on Friday, March 1st. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $49.67.

Biohaven Price Performance

NYSE BHVN opened at $57.02 on Thursday. The company has a market capitalization of $4.65 billion, a PE ratio of -10.07 and a beta of 1.18. The company has a fifty day moving average of $50.56 and a 200 day moving average of $37.95. Biohaven Ltd. has a 1 year low of $12.35 and a 1 year high of $62.21.

Biohaven (NYSE:BHVN) last issued its quarterly earnings data on Thursday, February 29th. The company reported ($1.81) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.41) by ($0.40). Research analysts expect that Biohaven Ltd. will post -5.85 earnings per share for the current year.

Biohaven Company Profile

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.